Safety and tolerability of topiramate and N-acetyl cysteine combination in individuals with alcohol use disorder: a 12 week, randomized, double-blind, pilot study.

IF 2.1 4区 医学 Q3 SUBSTANCE ABUSE Alcohol and alcoholism Pub Date : 2024-01-17 DOI:10.1093/alcalc/agad082
Nassima A-D Tiouririne, Tevfik Kalelioglu, Chamindi Seneviratne, Xin-Qun Wang
{"title":"Safety and tolerability of topiramate and N-acetyl cysteine combination in individuals with alcohol use disorder: a 12 week, randomized, double-blind, pilot study.","authors":"Nassima A-D Tiouririne, Tevfik Kalelioglu, Chamindi Seneviratne, Xin-Qun Wang","doi":"10.1093/alcalc/agad082","DOIUrl":null,"url":null,"abstract":"<p><p>Topiramate (TPM), a GABA/glutamate modulator, has shown positive results for treating alcohol use disorder (AUD), but causes significant cognitive adverse effects. TPM causes cognitive side effects by reducing glutathione levels in the frontal lobe. N-acetyl cysteine (NAC) increases level of intracellular glutathione. We hypothesized that combining NAC with TPM may mitigate the possible cognitive side effects of TPM, as well as working synergistically in reducing alcohol consumption more efficaciously than using TPM alone. A 12-week, double-blind randomized trial assessing the effects of combining NAC (1200 mg/day) with TPM (200 mg/day) vs TPM alone (i) cognitive side effects caused by TPM, (ii) percentage of heavy drinking days (PHDD) and percentage of days abstinent (PDA) using weekly calendar, and (iii) craving outcomes using the obsessive-compulsive drinking scale. Seventeen participants were randomized into the study (nine received TPM + NAC and eight matching TPM + Placebo). Cognitive adverse events were not significantly different between the treatment arms (P = 0.581). There was no difference in PHDD (P = 0.536) and in PDA over the entire study period (P = 0.892). However, both treatment groups at study end, compared with the baseline, significantly reduced their PHDD and increased their PDA. As for cravings: TPM + NAC group has shown higher level in automaticity of drinking (P = 0.029) and interference due to drinking (P = 0.014) subscales compared with the TPM + Placebo group. No difference was observed between groups in terms of Drinking Obsessions and Alcohol Consumption subscales. This pilot study indicates that combining NAC with TPM is overall safe, but the addition of NAC has no significant benefit over placebo in the incidence of TPM-related cognitive impairment, and alcohol drinking. Furthermore, craving outcomes may become worse with the addition of NAC.</p>","PeriodicalId":7407,"journal":{"name":"Alcohol and alcoholism","volume":" ","pages":""},"PeriodicalIF":2.1000,"publicationDate":"2024-01-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Alcohol and alcoholism","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/alcalc/agad082","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"SUBSTANCE ABUSE","Score":null,"Total":0}
引用次数: 0

Abstract

Topiramate (TPM), a GABA/glutamate modulator, has shown positive results for treating alcohol use disorder (AUD), but causes significant cognitive adverse effects. TPM causes cognitive side effects by reducing glutathione levels in the frontal lobe. N-acetyl cysteine (NAC) increases level of intracellular glutathione. We hypothesized that combining NAC with TPM may mitigate the possible cognitive side effects of TPM, as well as working synergistically in reducing alcohol consumption more efficaciously than using TPM alone. A 12-week, double-blind randomized trial assessing the effects of combining NAC (1200 mg/day) with TPM (200 mg/day) vs TPM alone (i) cognitive side effects caused by TPM, (ii) percentage of heavy drinking days (PHDD) and percentage of days abstinent (PDA) using weekly calendar, and (iii) craving outcomes using the obsessive-compulsive drinking scale. Seventeen participants were randomized into the study (nine received TPM + NAC and eight matching TPM + Placebo). Cognitive adverse events were not significantly different between the treatment arms (P = 0.581). There was no difference in PHDD (P = 0.536) and in PDA over the entire study period (P = 0.892). However, both treatment groups at study end, compared with the baseline, significantly reduced their PHDD and increased their PDA. As for cravings: TPM + NAC group has shown higher level in automaticity of drinking (P = 0.029) and interference due to drinking (P = 0.014) subscales compared with the TPM + Placebo group. No difference was observed between groups in terms of Drinking Obsessions and Alcohol Consumption subscales. This pilot study indicates that combining NAC with TPM is overall safe, but the addition of NAC has no significant benefit over placebo in the incidence of TPM-related cognitive impairment, and alcohol drinking. Furthermore, craving outcomes may become worse with the addition of NAC.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
托吡酯和 N-乙酰半胱氨酸复方制剂对酒精使用障碍患者的安全性和耐受性:一项为期 12 周的随机双盲试验研究。
托吡酯(TPM)是一种 GABA/谷氨酸调节剂,对治疗酒精使用障碍(AUD)有积极的效果,但会对认知产生明显的不良影响。TPM 会降低额叶中的谷胱甘肽水平,从而对认知产生副作用。N- 乙酰半胱氨酸(NAC)能提高细胞内谷胱甘肽的水平。我们假设,将 NAC 与 TPM 结合使用可减轻 TPM 可能对认知产生的副作用,同时在减少酒精消耗方面发挥协同作用,比单独使用 TPM 更有效。一项为期 12 周的双盲随机试验评估了将 NAC(1200 毫克/天)与 TPM(200 毫克/天)结合使用与单独使用 TPM 相比在以下方面的效果:(i) TPM 引起的认知副作用;(ii) 使用周历计算的大量饮酒天数百分比(PHDD)和戒酒天数百分比(PDA);(iii) 使用强迫性饮酒量表计算的渴求结果。17 名参与者被随机纳入研究(9 人接受 TPM + NAC,8 人接受 TPM + 安慰剂)。治疗组之间的认知不良事件无明显差异(P = 0.581)。在整个研究期间,PHDD(P = 0.536)和 PDA(P = 0.892)没有差异。不过,在研究结束时,与基线相比,两个治疗组的 PHDD 都显著降低,PDA 显著增加。至于渴望:与 TPM + 安慰剂组相比,TPM + NAC 组的饮酒自动性(P = 0.029)和饮酒干扰(P = 0.014)分量表水平更高。在 "饮酒强迫症 "和 "酒精消耗量 "分量表方面,各组之间没有差异。这项试点研究表明,将 NAC 与 TPM 结合使用总体上是安全的,但与安慰剂相比,添加 NAC 对 TPM 相关认知障碍和饮酒的发生率并无明显益处。此外,添加 NAC 后,渴求结果可能会变得更糟。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Alcohol and alcoholism
Alcohol and alcoholism 医学-药物滥用
CiteScore
4.70
自引率
3.60%
发文量
62
审稿时长
4-8 weeks
期刊介绍: About the Journal Alcohol and Alcoholism publishes papers on the biomedical, psychological, and sociological aspects of alcoholism and alcohol research, provided that they make a new and significant contribution to knowledge in the field. Papers include new results obtained experimentally, descriptions of new experimental (including clinical) methods of importance to the field of alcohol research and treatment, or new interpretations of existing results. Theoretical contributions are considered equally with papers dealing with experimental work provided that such theoretical contributions are not of a largely speculative or philosophical nature.
期刊最新文献
Comparative effects of topiramate and naltrexone on neural activity during anticipatory anxiety in individuals with alcohol use disorder. Are long-term alcohol health harms overlooked in individuals with illicit drug problems? Alcohol-related morbidity and mortality in a Danish cohort of clients in residential rehabilitation for drug use disorders. Correction to: A rapid literature review of the effect of alcohol marketing on people with, or at increased risk of, an alcohol problem. Prospective changes in drinking during the COVID-19 pandemic among adults with unhealthy alcohol use. Drinking motives link positive and negative life events to problematic alcohol use during the COVID-19 pandemic: a longitudinal study.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1